Dermagraft is a US Food and Drug Administration (FDA) approved skin substitute that helps heal diabetic foot ulcers
. These ulcers are serious wounds that occur most often in the skin over the ball of the foot or on the bottom of the big toe.
Helping to Grow New Skin
Dermagraft is a dissolvable mesh material that contains human connective tissue cells called fibroblasts. Dermagraft is placed directly on the ulcer, where the mesh and fibroblasts are gradually absorbed. Fibroblasts produce many of the same factors found in healthy skin. As the fibroblasts attach and grow in the wound, they help replace and rebuild the damaged parts in the foot.
Dermagraft can be used on the following types of ulcers:
- Full-thickness diabetic foot ulcers that have been present for longer than six weeks
- Ulcers that extend deeper into the skin where the blood vessels are, but do not involve tendon, muscle, joint capsule, or bone
When Not to Use Dermagraft
There are certain cases when Dermagraft should not be used, such as:
The Importance of Careful Foot Care
People with diabetes are more likely to develop foot problems such as:
- Changes in the skin of the feet, specifically drying and cracking
- Nerve damage, which decreases feeling in the feet and allows wounds to occur unnoticed
- Poor circulation, which makes fighting infection and wound healing difficult
These problems make people with diabetes more susceptible to sores. If you have diabetes, inspect your feet every day. Seek care right away if you have a foot injury. Also, have your feet checked by your doctor at least once a year.
American Diabetes Association
National Diabetes Information Clearinghouse
Canadian Diabetes Association
Canadian Podiatric Medical Association
Dermagraft—P000036. US Food and Drug Administration website. Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm085085.htm. Updated September 5, 2013. Accessed November 8, 2013.
Diabetic foot ulcer. EBSCO DynaMed website. Available at: https://dynamed.ebscohost.com/about/about-us. Updated October 7, 2013. Accessed November 8, 2013.
Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings.
Tissue Eng. 2006;12(9):2407-2424. Review.
Marston WA. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer.
Expert Rev Med Devices. 2004;1(1):21-31. Review.
Patient Guide. Hannibal Regional Medical Group website. Available at: http://hannibalregionalmedicalgroup.org/Portals/0/dermagraft%5Fpatient%5Fguide.pdf. Published 2008. Accessed November 8, 2013.